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because we can envisage cervical cancer elimination
Clinical trials of the both the bivalent and quadri-
valent vaccine demonstrated a level of cross-pro-
tection against certain closely-related HPV types. 
However, a meta-analysis of clinical trial data from 
both vaccines suggested that the cross-protective 
efficacy against HPV31/33/45 infection and asso-
ciated lesions was higher for the bivalent vaccine 
than the quadrivalent vaccine.1 Since 2006, several 
countries have introduced national HPV vaccina-
tion programmes but relatively few countries in-
troduced a national programme which exclusively 
adopted bivalent vaccine. Results of surveillance 
considering the population-level impact of HPV 
vaccination provide additional information to the 
clinical trials for several reasons. Firstly, in a real 
world setting, there may be some inequalities in 
who is being vaccinated, and secondly, that with 
high national vaccine coverage there will be a herd 
protection effect. Real-world post-vaccination sur-
veillance studies have demonstrated clear reduc-
tions in HPV16/18 infections in many countries. 
As expected, the changes in non-vaccine types, 
which are often rarer, have taken longer to emerge 
than the changes in vaccine types. However, sur-
veillance data from countries with a high-coverage 
David Mesher, PhD
Blood Safety, Hepatitis, Sexually 
Transmitted Infections (STI) and 
HIV Service, National Infection 
Service, Public Health England, 
London, UK
david.mesher@phe.gov.uk
Kevin Pollock, PhD, MPH
Health Protection Scotland, 
Meridian Court, Glasgow, UK
George Moore Building, School of  
Health and Life Sciences, Glasgow 
Caledonian University, Glasgow, UK.
Kevin.pollock@nhs.net
Kimberley Kavanagh, PhD
Department of  Mathematics and 




The population-level impact 
of bivalent HPV vaccination on 
closely related non-vaccine types
vaccination programme using the bivalent vaccine 
demonstrate substantial declines in some non-
16/18 HPV types. 
In Scotland, prevalence of HPV 31, 33 or 45 in 
those aged 20/21 attending for first cervical scree-
ning test declined from 14.2% in those born in 
1988 (unvaccinated cohort) to 2.6% in those 
born in 1995 (Figure 1).  All cross-protective types 
showed significant vaccine effectiveness in those 
vaccinated at age 12/13 (HPV type 31, 93.8%; 
HPV type 33, 79.1%; HPV type 45, 82.6%). Un-
vaccinated individuals born in 1995 had a reduced 
odds of HPV16/18 infection compared with tho-
se born in 1988 (adjusted odds ratio 0.13 [95% 
confidence interval (CI); 0.06–0.28]) and redu-
ced odds of HPV types 31, 33, and 45 (odds ratio 
0.45) indicative of herd protection in this cohort.2 
Recent post-vaccination surveillance data from 
young women attending for chlamydia screening 
in England has also demonstrated a decline in the 
prevalence of HPV31/33/45 infection from 9.4% 
in females born in 1996-1998 (prior to vaccine in-
troduction)  to 1.4% in those born in 1998 (Figu-
re 1).3 The estimated vaccine effectiveness against 
a meta-analysis of clinical trial data from both vaccines suggested 
that the cross-protective efficacy against HPV31/33/45 infection 
and associated lesions was higher for the bivalent vaccine than the 
quadrivalent vaccine
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HPV31, HPV33 and/or HPV45
Figure 1 
Prevalence of human papillomavirus (HPV) infection by year of birth and country
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HPV31/33/45 infection was 54.3% (95% CI; 
8.6%-77.2%) for women who would have been 
offered vaccination at age 15 or younger. 
Similar results of high vaccine-effectiveness have 
also been shown in other countries adopting the 
bivalent vaccine. For example, the results of a co-
hort study conducted in the Netherlands demons-
trated a vaccine effectiveness against HPV 31, 
33 and 45 persistent infections of 61.8% (95% 
CI; 16.7%-82.5%).4 On first glance, the declines 
seen in these countries appear inconsistent with 
Mathematical models which have suggested 
that herd protection could have a relatively 
greater impact on declines in types with a 
lower basic reproductive number, highlighting 
the importance of maintaining high 
vaccination coverage
the moderate cross-protective efficacy from the 
clinical trials. However, the results are consistent 
with theoretical findings from mathematical mo-
dels which have suggested that herd protection 
could have a relatively greater impact on declines 
in types with a lower basic reproductive number,5 
highlighting the importance of maintaining high 
vaccination coverage. 
In summary, the declines in the prevalence of 
HPV31/33/45 infection in England and Scot-
land since the introduction of national HPV 
vaccination have been substantial. Together with 
HPV16/18, these types are associated with around 
90% of cervical cancers in the UK. Elimination of 
these clinically relevant, high-risk HPV types in 
the United Kingdom is a real possibility and these 
data should inform assessments of the cost-effec-
tiveness of introducing the nonavalent vaccine to 
national vaccination programmes. 
1. Malagon T, Drolet M, Boily MC, et al. Cross-protective 
efficacy of two human papillomavirus vaccines: a systema-
tic review and meta-analysis. The Lancet Infectious disea-
ses 2012;12(10):781-9.
2. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in 
the prevalence of human papillomavirus following a 
national bivalent human papillomavirus vaccination pro-
gramme in Scotland: a 7-year cross-sectional study. The 
Lancet Infectious diseases 2017;17(12):1293-302.
3. Mesher D, Panwar K, Thomas SL, et al. The Impact of 
the National HPV Vaccination Program in England Using 
References:
the Bivalent HPV Vaccine: Surveillance of Type-Spe-
cific HPV in Young Females, 2010-2016. J Infect Dis 
2018;218(6):911-21.
4. Donken R, King AJ, Bogaards JA, et al. High Effective-
ness of the Bivalent Human Papillomavirus (HPV) Vaccine 
Against Incident and Persistent HPV Infections up to 6 
Years After Vaccination in Young Dutch Women. J Infect 
Dis 2018;217(10):1579-89.
5. Baussano I, Lazzarato F, Ronco G, et al. Different Cha-
llenges in Eliminating HPV16 Compared to Other Types: A 
Modeling Study. J Infect Dis 2017;216(3):336-44.
Quote this article as:
D Mesher, K Pollock, K Kavanagh (2018).  The population-level impact of bivalent HPV vaccination on closely related non-vaccine types  
www.HPVWorld.com, 74
HPVWorld is a project endorsed by
1 | 2
